Microbix Wins College of American Pathologists as New QAP Client

Microbix Biosystms ( (TSE:MBX) ) has issued an update.

Microbix Biosystems has secured the College of American Pathologists as a new client for its quality assessment products, which will be used in CAP’s global proficiency testing and external quality assessment programs for clinical laboratories. Multiple QAP product SKUs are already being supplied under confidential arrangements, with Microbix aiming to broaden its support across additional CAP programs and deepen the relationship through fiscal 2026 and beyond.

The deal underscores Microbix’s role as a specialist in safe, stable, patient-mimicking samples that validate diagnostic workflows end to end, leveraging its expertise in culturing and inactivating infectious disease pathogens. By aligning with CAP, one of the world’s leading laboratory quality organizations, Microbix enhances its industry positioning in lab quality assurance and potentially expands the reach and adoption of its QAPs among clinical labs that rely on CAP accreditation and proficiency testing services.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Spark’s Take on TSE:MBX Stock

According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.

Microbix Biosystems faces significant challenges in financial performance, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to a negative P/E ratio. However, the earnings call provides some optimism with operational improvements and a strong financial position, aiming for recovery in fiscal 2026.

To see Spark’s full report on TSE:MBX stock, click here.

More about Microbix Biosystms

Microbix Biosystems Inc. is a Canadian life sciences company that creates proprietary biological products for human health, supplying critical ingredients and devices to the global diagnostics industry. Its portfolio includes antigens for immunoassays, quality assessment products (QAPs), and QUANTDx reference materials used in clinical lab proficiency testing, assay development, and diagnostic workflow validation. Microbix employs over 120 staff, generates annual revenues of about C$18.6 million, and sells its QAPs in more than 30 countries through international distributors, operating under multiple quality and regulatory accreditations in North America, Europe, and Australia.

Average Trading Volume: 69,155

Technical Sentiment Signal: Sell

Current Market Cap: C$31.17M

Find detailed analytics on MBX stock on TipRanks’ Stock Analysis page.